en · de · es · fr · pt
peptide-index.peptides7501.com › Data › Mechanism And Preclinical Findings — Questions and Answers

Mechanism And Preclinical Findings — Questions and Answers

By Editorial Desk · published 2026-03-04 · last reviewed 2026-04-16 · Data

A practical reference on HPLC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-04-16. Anything still debated is marked as such rather than presented as settled.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Related pages on this site

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Supporting material

Humans commonly eat the livers of mammals, fowl, and fish as food. Domestic pig, ox, lamb, calf, chicken, and goose livers are widely available from butchers and supermarkets. In the Romance languages, the anatomical word for "liver" (French foie, Spanish hígado, etc.) derives not from the Latin anatomical term, jecur, but from the culinary term ficatum, literally "stuffed with figs", referring to the livers of geese that had been fattened on figs. Animal livers are rich in iron, vitamin A and vitamin B12; and cod liver oil is commonly used as a dietary supplement. Liver can be baked, boiled, broiled, fried, stir-fried, or eaten raw (asbeh nayeh or sawda naye in Lebanese cuisine, or liver sashimi in Japanese cuisine). In many preparations, pieces of liver are combined with pieces of meat or kidneys, as in the various forms of Middle Eastern mixed grill (e.g. meurav Yerushalmi). In the UK, kidney (including caul) was used alongside other organs like the lungs (known as "lights"), abdomen, heart was used as a poverty meal, which used up all of the animal. Other well-known examples include liver pâté, foie gras, chopped liver, and leverpastej. Liver sausages, such as Braunschweiger and liverwurst, are also a valued meal. Liver sausages may also be used as spreads. A traditional South African delicacy, skilpadjies, is made of minced lamb's liver wrapped in netvet (South African for caul fat), and grilled over an open fire. Traditionally, some fish livers were valued as food, especially the stingray liver.

lattice energy The energy released upon the formation of one mole of a crystalline ionic compound from its constituent ions, which are assumed to exist initially in the gaseous state. Lattice energy can be viewed as a measure of the cohesive forces that bind ionic solids; it is therefore directly related to many other physical properties of the solid, including solubility, hardness, and volatility.

Because β-alanine dipeptides are not incorporated into proteins, they can be stored at relatively high concentrations. Occurring at 17–25 mmol/kg (dry muscle), carnosine (β-alanyl-L-histidine) is an important intramuscular buffer, constituting 10-20% of the total buffering capacity in type I and II muscle fibres. In carnosine, the pKa of the imidazolium group is 6.83, which is ideal for buffering.

Sources: en.wikipedia.org

Supporting material

== Background == Gaines originally trained as a chemist and oceanographer, and received a master's degree from Scripps Institution of Oceanography in 1987. She has published peer-reviewed papers in The Journal of Organic Chemistry and the Journal of Chromatography A, as well as essays and short stories in an assortment of journals, literary magazines, and anthologies (Econ Papers, Nature, and The North American Review). She founded the "Fiction Meets Science" research and fellowship program at the University of Bremen.

=== Comparing PAM and BLOSUM === Although the PAM log-odds matrices were the first scoring matrices used with BLAST, the PAM matrices have largely been replaced by the BLOSUM matrices. Although both matrices produce similar scoring outcomes they were generated using differing methodologies. The BLOSUM matrices were generated directly from the amino acid differences in aligned blocks that have diverged to varying degrees the PAM matrices reflect the extrapolation of evolutionary information based on closely related sequences to longer timescales. Since scoring information for the PAM and BLOSUM matrices were generated in very different ways the numbers associated with the matrices have fundamentally different meanings; the numbers for PAM matrices increase for comparisons among more divergent proteins whereas the numbers for the BLOSUM matrices decrease. However, all amino acid substitution matrices can be compared in an information theoretic framework using their relative entropy.

1958 - Academician of Academia Sinica 1963 - Member of the American Academy of Arts and Sciences 1973 - Member of the United States National Academy of Sciences 1978 - Foreign Member of Chilean Academy of Sciences 1984 - Foreign Member of Indian Institute of Science

Supervised injection sites (SIS), or Drug consumption rooms (DCR), are legally sanctioned, medically supervised facilities designed to address public nuisance associated with drug use and provide a hygienic and stress-free environment for drug consumers. The facilities provide sterile injection equipment, information about drugs and basic health care, treatment referrals, and access to medical staff. Some offer counseling, hygienic and other services of use to itinerant and impoverished individuals. Most programmes prohibit the sale or purchase of illegal drugs. Many require identification cards. Some restrict access to local residents and apply other admission criteria, such as they have to be people who inject substances, but generally in Europe they do not exclude people with substance use disorders who consume their substances through other means. The Netherlands had the first staffed injection room, although they did not operate under explicit legal support until 1996. Instead, the first center where it was legal to inject drugs was in Berne, Switzerland, opened 1986. In 1994, Germany opened its first site. Although, as in the Netherlands they operated in a "gray area", supported by the local authorities and with consent from the police until the Bundestag provided a legal exemption in 2000. In Europe, Luxembourg, Spain and Norway have opened facilities after year 2000. Sydney's Medically Supervised Injecting Center (MSIC) was established in May 2001 as a trial and Vancouver's Insite opened in September 2003.

Sources: en.wikipedia.org

Supporting material

The density of francium is expected to be around 2.48 g/cm3 (Mendeleev's method extrapolates 2.4 g/cm3). Another calculation gives a much higher value of 3.57 g/cm3. Francium is predicted to have a bulk modulus of 2.1–2.6 GPa. Linus Pauling estimated the electronegativity of francium at 0.7 on the Pauling scale, the same as caesium; the value for caesium has since been refined to 0.79, but there are no experimental data to allow a refinement of the value for francium. Francium has a slightly higher ionization energy than caesium, 392.811(4) kJ/mol as opposed to 375.7041(2) kJ/mol for caesium, as would be expected from relativistic effects, and this would imply that caesium is the less electronegative of the two. Francium should also have a higher electron affinity than caesium and the Fr− ion should be more polarizable than the Cs− ion.

== Names == Dapagliflozin is the international nonproprietary name (INN), and the United States Adopted Name (USAN). The fixed-dose combination product, dapagliflozin/metformin extended-release, is sold under the brand name Xigduo XR. In July 2016, the fixed-dose combination of saxagliptin and dapagliflozin was authorized for medical use in the European Union and is sold under the brand name Qtern. The combination drug was approved for medical use in the United States in February 2017, where it also is sold under the brand name Qtern. In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in adults with type 2 diabetes when used in combination with diet and exercise. The FDA granted the approval of Qternmet XR to AstraZeneca. The combination drug was authorized for use in the European Union in November 2019, and is sold under the brand name Qtrilmet.

=== History === The lineage of the 1st Transportation Detachment, 2nd Mobile Corps dates back to the 2nd World War, when it was known as the Laiyuan guerilla detachment of the Jin-Cha-Ji Military district. It participated in the Chinese civil war, WW2 and the Korean war. After becoming part of the PLA Basic Engineering Corps it was deployed to build the Duku Highway in 1974 in which 47 personnel lost their lives. Prior to 1984, the transportation corps was part of the People's Liberation Army Basic Engineering Corps. The 7th Transportation Detachment assisted in disaster relief after the 2015 Tianjin explosions. The 6th Detachment of the transportation corps deployed 105 officers and 48 vehicles for urban search and rescue duties during the 2015 Shenzhen landslide.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

Network